Close

Roche to acquire Telavant from Roivant and Pfizer for $7.25 billion Oct 23, 2023 06:25AM
Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant Oct 23, 2023 01:00AM
Roivant to Participate in September Investor Events Aug 30, 2022 07:00AM
Roivant to Participate in September Investor Events Aug 30, 2022 07:00AM
Roivant Sciences Announces Close of Business Combination with Montes Archimedes Acquisition Corp. and Concurrent PIPE Financing Oct 1, 2021 08:00AM


May 3, 2021 07:01AM Roivant Sciences and Montes Archimedes Acquisition Corp. (MAAC) to Combine and Create Publicly Traded Leader in Biopharma and Health Technology